Modified, human immunodeficiency virus (HIV) -inoculated thy/liv -SCID-hu mice were used to evaluate the in vivo efficacy of antiretroviral drugs. Ritonavir treatment alone initially suppressed plasma viremia, but the viremia recurred with the appearance of ritonavir-resistant HIV isolates. Multidrug therapy suppressed plasma HIV RNA to undetectable levels; however, plasma viremia returned after therapy was stopped, showing that the therapy did not completely suppress HIV infection in the thymic implant. When thy/liv -SCID-hu mice were treated with a combination of zidovudine, lamivudine, and ritonavir immediately after inoculation with HIV, cocultures of the thymic implants remained negative for HIV even 1 month after therapy was discontinued, suggesting that acute treatment can prevent the establishment of HIV infection. Thus, these modified thy/liv -SCID-hu mice should prove to be a useful system for evaluating the effectiveness of different antiretroviral therapies on acute and chronic HIV infection.
Recent advances in understanding the pathophysiology of
Because the lymphoid tissues are the major site of HIV replication [7, 8] , it is important to evaluate whether these human immunodeficiency virus (HIV) infection coupled with the development of potent therapeutic agents have revolutiontherapeutic approaches also suppress HIV replication in the lymphoid compartment. If they do, it will be necessary to ized the treatment of HIV-infected persons [1] . Treatment with HIV protease inhibitors, such as saquinavir and ritonavir, can ascertain whether there is still a long-lived, latently infected cell population, such as macrophages, resting T cells, or stem/ markedly decrease HIV virus load and increase peripheral CD4 / T cell counts in HIV-infected persons [2, 3] . These progenitor cells, that may function as a viral reservoir to be reactivated after the withdrawal of therapy. However, perforeffects can be enhanced significantly by the addition of two other anti-HIV agents, zidovudine and zalcitabine, to the theramance of these studies in HIV-infected subjects is limited by the difficulty of frequently accessing lymphoid tissue for analypeutic regimen [4, 5] . Combination therapy with protease inhibitors and reverse transcriptase (RT) inhibitors, such as zidovusis. Furthermore, testing the efficacy of newer, unproved antiretroviral drugs and novel drug combinations in patients is dine and lamivudine (3TC), can reduce plasma HIV RNA to undetectable levels and may even prevent HIV infection when restricted by ethical constraints due to the availability of other treatments with known effectiveness. Therefore, there is a given acutely [5, 6] .
pressing need to develop in vivo systems for evaluating the activity of various antiretroviral drug combinations against a spectrum of HIV isolates with different biologic behaviors. There is also a need for evaluating the effect of these treatments [9, 10] . By modifying the Medicine were followed in animal studies.
technique of implanting human fetal thymus and liver into SCID ated HIV infection after intraimplant or intraperitoneal inocula-JID 1998;177 (February) Administration of drugs and measurement of saquinavir and treatment with interleukin-10 can inhibit HIV infection [12, 13] .
ritonavir levels. Drugs were administered to the mice by mixing
In the current study, we demonstrate the usefulness of these the indicated drugs with powdered animal feed and then adding thy/liv-SCID-hu mice for evaluating the effects of multidrug the mixture to feeding jars that were designed to minimize spillage. therapy on in vivo HIV infection.
The drug dosage for each mouse (each weighing Ç25 g) were calculated on the basis of their average oral intake of 5 g of feed/ day. The thy/liv-SCID-hu mice were housed singly so that drug
Materials and Methods
consumption could be confirmed by measurement of the quantity of feed consumed. Saquinavir and ritonavir in plasma samples were Implantation of human thymic and liver tissue into SCID mice.
quantitatively analyzed by Oneida Research Services (Whitesboro, Fetal thymic and liver tissue (hu-thy/liv) were obtained from 17-NY), using a specific high-pressure liquid chromatography to 21-gestational week-old human fetuses within 8 h after the (HPLC)-UV method. elective termination of pregnancy and implanted into SCID mice Unknown, spiked standard and quality control samples were (6-8 weeks old) as described [11, 12] . In brief, human fetal thymus extracted from plasma with an organic solution and then evapoand liver tissue obtained from the same fetus were cut into 1-mm 3 rated to dryness with nitrogen, reconstituted in an aqueous solution, sections. After the SCID mice were anesthetized with pentobarbital and analyzed by reverse-phase HPLC within a linear range of 100-(40-80 mg/kg), the left and right kidneys were sequentially exteri-3500 ng/mL. Standard curves were constructed from the peak orized and subcapsularly implanted with at least 10 pieces of synheight ratios of the drug to internal standards, using weighted geneic thymus and liver tissue. The procedure was associated with linear regression analysis. Plasma levels of quality control samples minimal morbidity and mortality, and ú95% of the mice were and ''unknowns'' were then calculated with respect to the standard successfully implanted. By 3 months after transplantation, the imcurve. planted tissue had increased ú20-fold in size.
Titration of HIV-infected mononuclear cells in the hu-thy/liv Flow cytometry. Mononuclear cells were harvested from the
implant by limiting-dilution coculture. The number of HIV-1-hu-thy/liv implants of the thy/liv-SCID-hu mice and stained with infected mononuclear cells present in the hu-thy/liv implants was peridinin-chlorophyll protein-conjugated monoclonal antibody measured by quantitative coculture as described [12] . Five-fold (MAb) to human CD45, fluorescein isothiocyanate-conjugated dilutions (ranging from 1 1 10 6 cells to 3.2 1 10 2 cells) of mononuMAb to human CD4, and phycoerythrin-conjugated MAb to huclear cells from the hu-thy/liv implants were cultured in quadrupliman CD8 (Becton Dickinson, Mountain View, CA) as described cate at 37ЊC in 24-well plates with PHA-activated donor mononu- [11] . Expression of human CD4 and CD8 by lymphocytes present clear cells (1.0 1 10 6 ) in 2.0 mL of RPMI 1640 containing fetal in the mice was assessed by three-color flow cytometry, using a calf serum (10% vol/vol) and interleukin-2 (32 U/mL). After 1 to cell analyzer and computer software (FACScan and LYSIS-II; 2 weeks, the p24 antigen content of the culture supernatant was Becton Dickinson). Expression of human CD45 was used to conmeasured using the HIV-1 p24 core profile ELISA assay (DuPont firm the human origin of the cells. Lymphocyte gates were set on NEN, Wilmington, DE). The lowest number of added mononuclear the basis of forward-and side-scatter profiles corresponding to cells that infected at least half of the quadruplicate cultures with gates set for control human lymphocytes from healthy adult volun-HIV-1 was taken as the end point or TCID; data are presented as teers. Nonviable cells and unlysed red blood cells were excluded TCID/10 6 mononuclear cells as described [12] . from analysis on the basis of their forward-and side-scatter proQuantitation of plasma HIV RNA levels. Amplicor HIV-1 files. Cutoff values for the quadrants as well as compensation for monitor kits (provided by Roche Diagnostic Systems, Branchburg, phycoerythrin versus fluorescein isothiocyanate versus peridinin-NJ) were used, according to the manufacturer's recommended prochlorophyll protein emission was determined on the basis of single, tocol, to quantitate HIV RNA in mouse plasma. The kits can double, and triple staining of positive (human adult) and negative quantitate virion-associated HIV-1 RNA in plasma at concentracontrol (C.B-17 mouse) mononuclear cells with antibodies to hutions as low as 400 RNA copies/mL. The internal HIV quantitation man CD4, CD8, and CD45 and staining with the appropriate mouse standard (QS), a synthetic RNA molecule with primer binding IgG isotype controls.
sites identical to the HIV target and a unique internal probe seInfection of thy/liv-SCID-hu mice with HIV. The HIV strain quence specific to the QS RNA molecule, was added to 200 mL used in this study, HIV-1 59 , is a primary, monocyte-tropic, nonsynof each plasma sample. RNA was then extracted with a lysis cytium-inducing isolate that was derived from peripheral blood reagent containing guanidine thiocyanate, precipitated with isopromononuclear cells (PBMC) from a 17-month-old HIV-1-infected panol, and resuspended in reaction buffer. A 142-bp sequence child. The strain, which was derived by coculture with phytohein the HIV gag gene was amplified by reverse transcription and magglutinin (PHA)-activated donor PBMC, was expanded by anpolymerase chain reaction (PCR), using recombinant Thermus other round of coculture with PHA-activated PBMC and then dithermophilus DNA polymerase and biotinylated primers SK431 vided into aliquots that were frozen in liquid nitrogen as described and SK462. PCR product contamination was controlled by incor- [12] . Mice were infected by direct injection of 300 TCID 50 of porating dUTP during the PCR reaction and then treating all sam-HIV-1 59 in a volume of 30 mL into the left hu-thy/liv implant. To ples with AmpErase (from the Amplicor kit) prior to PCR to control for variability due to the source of donor tissue, mice eliminate carryover of any dUTP-containing PCR product. engrafted with the same donor tissue were distributed into each
The biotinylated HIV and QS amplicons were detected in sepatreatment group. All tissue was screened and shown to be homozyrate wells of a microwell plate coated with HIV-specific and QS-specific oligonucleotide probes, respectively, using avidingous for the normal CCR5 allele.
horseradish peroxidase conjugate and a colorimetric reaction for horseradish peroxidase. To measure the HIV and QS amplicons in a dynamic range from 400 to 750,000 copies/mL, 5-fold serial dilutions of the amplicons were made in the HIV-specific and QS-specific wells of the microplate (rows A-F and G-H, respectively). The HIV RNA copy number was then calculated from the known input copy number of the QS RNA, the optical densities at 450 nm of the HIV and the QS wells that fell within a defined range, and the dilution factors associated with the selected wells.
Sequence analysis of the protease gene. DNA was isolated from the HIV-infected hu-thy/liv implants, and the protease coding region was amplified by PCR, using the primers and conditions described [14] . The amplified products were cloned (TA cloning kit; InVitrogen, Carlsbad, CA) and sequenced using the dideoxychain termination method.
Statistical analysis. The Student's t test for unpaired data was used for all statistical comparisons.
Results
Pharmacokinetic analysis of absorption of saquinavir and ritonavir. Saquinavir and ritonavir are symmetry-based HIV protease inhibitors that inhibit proteolysis of the gag and gagpol proteins and render newly formed HIV particles noninfectious [2, 3] . To determine whether therapeutic levels of these drugs could be obtained in mice by oral administration, we mixed saquinavir alone (2500 mg/kg), ritonavir alone (200 mg/kg), or a combination of saquinavir-ritonavir (2500 and 200 mg/kg, respectively) with powdered animal feed and administered it to the mice in spill-resistant feeding jars. The saquinavir-ritonavir combination was examined because ritonavir dramatically increases saquinavir levels in animals and humans [15] by inhibiting CYP3A4, the isoform of cytochrome P450 that is responsible for the metabolic clearance of saquinavir, thereby potentially enhancing the anti-HIV activity of had levels that ranged from 6000 ng/mL in the late morning to 2000 ng/mL at night and that were comparable to peak levels reported for humans treated with one 500-mg dose of ritonavir saquinavir levels could be markedly enhanced by the coadministration of ritonavir. [17] . Saquinavir-treated mice (n Å 4) had plasma levels of 200-600 ng/mL, which were similar to levels in humans treated with
Evaluation of the kinetics of HIV replication in thy/liv -SCID-hu mice. Because therapeutic levels of ritonavir were 7200 mg of saquinavir/day [18] .
Plasma levels of ritonavir in mice treated with the ritonavirobtained in mice after oral administration of the drug and because our HIV-infected thy/liv -SCID-hu mice developed saquinavir combination did not differ significantly from those in mice treated with ritonavir alone (P õ .31). In contrast, plasma viremia [13] , the kinetics of HIV replication in these mice were determined by measuring the rate of plasma HIV plasma levels of saquinavir in mice treated with the drug combination were significantly increased compared with levels in RNA decline after the initiation of ritonavir therapy as described in studies with HIV-infected persons [19] . Six mice mice treated with saquinavir alone (P õ .02).
Taken together, these data indicated that therapeutic levels were infected by intraimplant injection with HIV-1 59 , and 5 weeks later, after steady-state plasma HIV RNA levels were of ritonavir and saquinavir were obtained in mice treated by oral administration of drug admixed with their feed and that attained, the mice were started on ritonavir treatment (200 / 9d3f$$fe45 12-23-97 08:09:06 jinfas UC: J Infect mg/kg/day). Blood samples were obtained at frequent intervals, ritonavir, the other 2 thy/liv -SCID-hu mice, 216c4 and 216c2, had recurrence of plasma viremia 37 days and 3 months after and plasma HIV RNA was measured by use of an extremely sensitive assay (Amplicor HIV-1 monitor; Roche Diagnostics). treatment was started, respectively. The degree of cellular HIV infection in these 2 mice was evaluated by determining the The temporal response of plasma HIV RNA levels to ritonavir therapy in a representative HIV-infected thy/livnumber of HIV-infected cells in a hu-thy/liv implant biopsy:
The implants had significant HIV infection (3125 and 25 TCID/ SCID-hu mouse example is shown in figure 2. Attainment of a steady state virus load before the initiation of therapy 10 6 thymocytes, respectively) despite the continued ritonavir treatment. was indicated by the measurement of similar levels of HIV RNA in the plasma at two time points that were 7 days apart.
To determine if the HIV-1 isolates infecting these mice had developed a decreased sensitivity to ritonavir, the initial inocuNo significant decrease in HIV RNA levels was observed during the first 3 days of treatment, but between the fourth lum of HIV-1 59 and the HIV isolated from these hu-thy/liv implants after 3 months of ritonavir treatment were tested for and eighth days of therapy, plasma HIV RNA levels declined rapidly to õ5% of the baseline levels. These low levels of their sensitivity to ritonavir as described [20] . In contrast to the initial inoculum of HIV-1 59 , which had an IC 90 by ritonavir plasma viremia persisted for an additional 7 to 8 days, after which time, HIV RNA was no longer detectable in the of Ç0.1 mM, HIV isolated from the ritonavir-treated thy/liv -SCID-hu mice had an Ç3-fold (216c4 isolate) or 7-fold (216c2 plasma.
Analysis of the acute drop in HIV RNA levels with the matheisolate) higher IC 90 of Ç0.3 mM and 0.7 mM, respectively (figure 3). The greater resistance to ritonavir that was exhibited matical model described by Perelson et al. [19] for in vivo HIV dynamics in HIV-infected humans was used to determine the by the HIV isolated from mouse 216c2 (compared with the HIV from mouse 216c4) was paralleled by a higher virus load decay rate constants for plasma virions (c) and infected cells (d) and the total virion production in the HIV-infected thy/liv-SCIDin the 216c2 hu -thy/liv implant.
To determine if the appearance of isolates displaying phenohu mice (table 1) . In mice analyzed with this model, the mean average life span of an extracellular virion was 0.34 days and of typic resistance to ritonavir was associated with specific genotypic changes in the protease gene, proviral DNA from the a productively infected cell was 1.89 days.
In vivo development of ritonavir-resistant isolates during biopsied hu-thy/liv implants was amplified by PCR, using primers that flanked the protease gene, and then sequenced. In conprolonged monotherapy. After the 6 thy/liv -SCID-hu mice were treated with ritonavir for 16 days, they had no detectable trast to the protease gene sequence in the initial inoculum of HIV-1 59 , the protease region of the HIV isolated from the HIV RNA in their plasma. When ritonavir treatment was stopped in 4 of these mice, plasma viremia recurred within 2 216c2 hu-thy/liv implant had a mutation at position 84 from isoleucine to valine (I84V), and the HIV isolated from the days and returned to pretreatment levels 6 days later. Of great interest was the observation that despite being continued on 216c4 hu-thy/liv implant had a mutation at position 82 from valine to alanine (V82A). Both of these mutations confer increased resistance to ritonavir [21] .
Comparison of the effects of multidrug therapy on plasma viremia and HIV infection in the hu-thy/liv implant. Suppression of cellular HIV infection and plasma viremia by multidrug therapy in our modified thy/liv -SCID-hu mice was investigated by treatment either with a combination of RT and protease inhibitors (zidovudine-3TC-ritonavir) that markedly suppress plasma viremia in HIV-infected persons [5] or with two protease inhibitors (saquinavir and ritonavir). The mice were infected with HIV-1 59 by direct inoculation of 300 TCID 50 into the left hu-thy/liv implant, and the mice were evaluated 1 month later (by which time systemic HIV infection occurs [13] ) by measuring plasma HIV RNA levels and performing quantitative coculture on a biopsy of the left hu-thy/liv implant. Some mice were then started on a combination of zidovudine-3TC-ritonavir (100, 100, and 200 mg/kg/day, respectively; n Å 3) and 2500 mg/kg/day, respectively; n Å 2).
followed until steady-state plasma HIV RNA levels were attained.
After 1 month of therapy, the effect of these therapeutic On day 0, mice were started on ritonavir (200 mg/kg/day), and plasma HIV RNA levels were determined at indicated times. 
Total virion production was calculated based on assumption that plasma and extracellular fluid were in equilibrium.
of the plasma HIV RNA and by quantitative coculture of a To determine whether these few infected cells could function repeat biopsy of the left hu-thy/liv implant. In contrast to the as an infectious reservoir, we took some mice off therapy. One untreated mice, in which plasma viremia continued to increase, month later, the plasma HIV RNA levels and virus loads in a HIV RNA was no longer detectable in the plasma of mice repeat biopsy of the hu-thy/liv implant were measured. Plasma treated with any of the multidrug regimens ( figure 4A ). Multiviremia recurred in all of the multidrug-treated thy/liv -SCIDdrug therapy also suppressed the virus load in the thy/liv imhu mice examined, including 1 mouse treated with high-dose plants of these mice so that only low levels of HIV infection zidovudine-3TC-ritonavir (2832 copies of HIV RNA/mL), 2 were still present (figure 4B).
mice treated with lower-dose zidovudine-3TC-ritonavir (7410 and 947 copies of HIV RNA/mL), and 1 mouse treated with ritonavir-saquinavir (1004 copies of HIV RNA/mL). This was paralleled by a marked increase in the virus loads in the huthy/liv implants of the mouse treated with high-dose zidovudine-3TC-ritonavir (625 TCID/10 6 cells), the 2 mice treated with lower-dose zidovudine-3TC-ritonavir (both 3125 TCID/ 10 6 cells), and the mouse treated with ritonavir-saquinavir (3125 TCID/10 6 cells). In the human thymic implants of the thy/liv -SCID-hu mice treated with zidovudine-3TC-ritonavir, a dose-responsive decrease in the CD4/CD8 double-positive thymocyte population occurred that was not observed in untreated mice or mice treated with ritonavir-saquinavir (figure 4C). Because thymopoiesis in the human thymic implant depends on continued hematopoietic activity by the coimplanted human fetal liver to provide new pre-T cells [9] , production of immature thymocytes may be inhibited by the suppressive effects of zidovudine and 3TC on hematopoiesis [22, 23] . Therefore it is likely that zidovudine-3TC-ritonavir (100, 100, 200 mg/kg/day, respec-(figure 5A). HIV was detected in the hu-thy/liv implants from all untreated mice and from all 5 mice treated with the lower tively; n Å 5), zidovudine-3TC-ritonavir (10, 10, 20 mg/kg/ day, respectively; n Å 4), ritonavir-saquinavir (200 and 2500 dose of ritonavir-saquinavir. HIV was not detected in implants from any of the 5 mice treated with the higher dose of zidovumg/kg/day, respectively; n Å 4), or ritonavir-saquinavir (20 and 250 mg/kg/day, respectively; n Å 5). lower dose of zidovudine-3TC-ritonavir (P Å .03) or in the by quantitative coculture of the left and right hu-thy/liv implants ( figure 5A ) and by measurement of plasma HIV implants from 3 of 4 mice treated with the higher dose of ritonavir-saquinavir (P Å .033).
RNA ( figure 5B ). Unfortunately, some of the mice died after the first biopsy and were, therefore, not available for Because prevention, as opposed to suppression, of HIV infection by multidrug therapy would be indicated by reanalysis.
In the surviving mice, HIV infection was still not detectable the continued absence of infection after therapy was discontinued, drug treatment was stopped for all mice. One by coculture of the thymic implants in the hu-thy/liv implants or the plasma from 3 of 3 mice that had been treated with the month later, the mice were reevaluated for HIV infection / 9d3f$$fe45
12-23-97 08:09:06 jinfas UC: J Infect higher dosage of zidovudine-3TC-ritonavir (100, 100, and 200 be used as an indicator of the degree of viral replication occurring in the lymphoid tissues [24] . The rapid rate by which mg/kg/day, respectively). In addition, no HIV DNA was detected by PCR in the hu-thy/liv implants from 2 of these mice, plasma HIV RNA levels decline in HIV-infected persons after treatment with potent antiretroviral drugs indicates that the and no HIV RNA was detectable by reverse transcription -PCR in the hu-thy/liv implants from the 3 mice (data not plasma HIV population turns over rapidly, contains the most recently replicated HIV, and may be used as a sensitive indicashown). In contrast, HIV infection was detected by coculture in 2 of 2 mice treated with the lower dosage of zidovudinetor of the effects of therapeutic interventions on HIV replication [6, 19, 25, 26] . 3TC-ritonavir (10, 10, and 20 mg/kg/day, respectively) and in 1 of 2 mice treated with the higher dosage of ritonavir-saquiUsing a mathematical model described for HIV-infected persons [19], we analyzed the ritonavir-induced decline in plasma navir (200 and 2500 mg/kg/day, respectively) that had been negative when evaluated immediately after therapy was HIV RNA levels in HIV-infected thy/liv -SCID-hu mice. The average life span of an extracellular virion was Ç0.34 days, stopped.
Although normal thymopoiesis was observed in the hu-thy/ with a t 1/2 of 0.29 days, and the average life span of productively HIV-infected cells was Ç1.89 days, with a t 1/2 of 1.37 days. liv implants from the HIV-infected thy/liv -SCID-hu mice that were either untreated or treated with ritonavir-saquinavir, These results were comparable to those reported for HIV-infected persons with an average extracellular virion life span of depletion of the immature CD4/CD8 double-positive population occurred in the implants of the mice treated with the higher 0.3 days, with a t 1/2 of 0.24 days, and an average life span of productively infected cells of 2.2 days, with a t 1/2 of 1.6 days dosage of zidovudine-3TC-ritonavir (100, 100, and 200 mg/ kg/day, respectively) ( figure 5C ). The reversible nature of this [19] . Because these mice do not mount a detectable human or mouse response to HIV [12] , these data suggest that the rate suppression was demonstrated by the marked increase of the immature CD4/CD8 double-positive thymocyte population in of viral and cellular turnover is predominantly a function of HIV replication and not of the immune response directed the hu-thy/liv implants 1 month after therapy was stopped. This indicated, as described above, that the suppression of against HIV. Nevertheless, because turnover of HIV-infected thymocytes may differ from that of HIV-infected peripheral T thymopoiesis was due to the toxic effect of zidovudine and 3TC on hematopoiesis and pre -T cell development.
cells, the mathematical model for T cell decay proposed for HIV-infected patients may not be applicable for the analysis of the kinetics of infected T cell turnover in our hu-thy/livDiscussion SCID-hu mice. The mice displayed lower total daily virion production (6.2 In the current study, we report on the utility of our modified thy/liv -SCID-hu mice to study the in vivo effects of antiret-1 10 4 virions/day) than that reported in humans (10.3 1 10 9 virions/day) [19] , but this was expected considering the roviral drug therapy on HIV infection. After inoculation with HIV, these mice developed extensive HIV infection in the Ç3000-fold -larger body mass of humans compared with mice and the smaller population of human T cells present in the hu-thy/liv implants and plasma viremia that displayed rapid turnover, with an average life span of 0.34 days. The high level mice. Although plasma HIV levels rapidly declined by 95% within 8 days after the initiation of ritonavir, it took an addiof HIV replication in the thy/liv -SCID-hu mice was further indicated by the rapid appearance of HIV with decreased sensitional 7 to 8 days until HIV RNA was no longer detectable in the plasma. It is likely that the second phase of viral decay tivity to ritonavir during monotherapy with ritonavir.
We demonstrated that these mice could be used as a system observed in these thy/liv -SCID-hu mice is attributable to the release of virus into the plasma by secondary sources, such as to correlate the effects of combination drug therapy on HIV cellular infection in the thy/liv implant with the effect on infected macrophages or dendritic cells, the activation of latently infected T cells or the release of trapped virions, as plasma viremia. Multidrug therapy of thy/liv -SCID-hu mice with established HIV infection with either zidovudine-3TC-recently described for HIV-infected persons [27] . Taken together, these results demonstrate that the kinetics ritonavir or saquinavir-ritonavir suppressed plasma viremia to undetectable levels and potently decreased cellular infection in of HIV replication in our thy/liv -SCID-hu mice closely resemble that reported in HIV-infected persons and suggest that these the hu-thy/liv implants, but plasma viremia recurred after therapy was stopped. However, immediate treatment with high mice should be a useful model to study in vivo HIV infection. Although plasma viremia was initially completely supdoses of zidovudine-3TC-ritonavir was effective in preventing HIV infection, which was indicated by the fact that HIV could pressed in thy/liv -SCID-hu mice by treatment with ritonavir, it recurred despite continuation of ritonavir therapy and was not be cultured from the hu-thy/liv implants of these thy/liv -SCID-hu mice even after they were off drug therapy for 1 associated with extensive infection of the hu-thy/liv implants. HIV isolated from the implants was 3-to 7-fold less susceptible month.
High levels of HIV RNA are present in the plasma of HIVto ritonavir than the initial HIV inoculum, indicating that HIV replicated in the infected thy/liv -SCID-hu mice at a rate suffiinfected persons during all stages of HIV infection and may / 9d3f$$fe45
12-23-97 08:09:06 jinfas UC: J Infect cient to generate mutations that could confer resistance to ritolymphoid tissues in HIV-infected patients treated with multidrug therapy [31] . One month after therapy was stopped in these mice, navir [6] . This was confirmed by demonstrating that genotypic changes associated with the development of ritonavir resistance plasma viremia recurred in tandem with increased cellular infection in the hu-thy/liv implants. were present in the protease gene of the HIV isolated from thy/liv -SCID-hu mice, a valine-to-alanine change at position In addition to investigating the effect of multidrug therapy on established HIV infection, we also examined the capacity 82 (V82A) in mouse 216c4 and an isoleucine-to-valine substitution at position 84 (I84V) in mouse 216c2 [21] . These two of multidrug therapy initiated immediately after inoculation with HIV to prevent subsequent in vivo HIV infection. We mutations develop in ritonavir-treated patients, with the V82A change being the most frequently observed mutation, and in demonstrated that different therapeutic regimens had different capacities to prevent HIV infection. Although HIV could not most patients, the first to emerge [28, 29] .
The association between the recurrence of plasma viremia be detected by coculture in the hu-thy/liv implants immediately after treatment with the lower dosage of zidovudine-3TC-ritowith the appearance of ritonavir-resistant isolates in the ritonavir-treated mice was similar to that observed in ritonavirnavir (10, 10, and 20 mg/kg/day, respectively) or with ritonavirsaquinavir (200 and 2500 mg/kg/day, respectively) was treated patients [29] . Thus, these thy/liv -SCID-hu mice should prove to be a useful in vivo system for investigating the emerstopped, active HIV infection was present 1 month after drug therapy was terminated. These data indicated that HIV infection gence of drug-resistant isolates, including the role of variables, such as drug dosing, and the use of different drug combinations.
had been suppressed by these treatments, not prevented, and, therefore, after therapy was discontinued, extremely low levels Because we demonstrated that therapeutic levels of antiretroviral drugs could be obtained by oral administration, these modified of HIV present in these lymphoid tissues served as a reservoir to initiate recurrence of active HIV infection. thy/liv-SCID-hu mice could be used to investigate the effect of multidrug therapy, given by dietary admixture, on lymphoid tissue
In contrast, when thy/liv -SCID-hu mice were treated with the higher dosage of zidovudine-3TC-ritonavir (100, 100, 200 infection and plasma viremia. Previous studies had demonstrated that SCID-hu mice could be used to assess the in vivo antiviral mg/kg/day, respectively), no HIV was detected in the hu-thy/ liv implants by coculture even 1 month after therapy was effects of zidovudine after HIV was inoculated into their human thymic implants [30] . However, the resultant HIV infection in stopped. This indicates that when given at the appropriate dose, the combination of RT inhibitors with protease inhibitors might those SCID-hu mice was limited to the thymic implant and was not associated with the presence of plasma viremia. Therefore, successfully prevent HIV infection. These observations have major potential implications for the the use of our modified thy/liv-SCID-hu mice, which develop high levels of disseminated HIV infection, to correlate the effect evaluation and clinical treatment of persons treated with potent anti-HIV therapy soon after acute infection, such as infants of multidrug therapy on plasma viremia with its effect on the level of cellular infection represents a major advance for assessing born to HIV-infected mothers or persons presenting acutely after high-risk exposure. Although this combination appeared the in vivo effect of antiretroviral therapy.
The mice were treated with a combination of two RT inhibito be more effective in preventing HIV infection than the combination of two protease inhibitors, ritonavir and saquinavir, it tors (zidovudine and 3TC) and a protease inhibitor (ritonavir) or with a combination of two protease inhibitors (ritonavir and was associated with significant suppression of thymopoiesis in the hu-thy/liv implant. It is possible that HIV infection would saquinavir). Ritonavir was used as a representative protease inhibitor, and comparable effects could presumably have been be detectable in the hu-thy/liv implants of these mice if they were examined after being without therapy for ú1 month. achieved by a similar combination of different protease and RT inhibitors. The combination of ritonavir and saquinavir was However, because the hu-thy/liv implant contains a high concentration of thymocytes that are extremely sensitive to HIV chosen to take advantage of the inhibitory effect of ritonavir on the metabolic clearance of saquinavir [15] .
infection, it is likely that any HIV present in tissue would have initiated a detectable infection by 1 month, as observed in the The presence of plasma viremia in the HIV-infected thy/liv-SCID-hu mice permitted us to examine the effect of treatment mice treated with lower doses of zidovudine-3TC-ritonavir or with ritonavir-saquinavir. with multidrug therapy on plasma HIV levels and to correlate it with the level of infection in the hu-thy/liv implant. Plasma vireAlthough the thy/liv -SCID-hu model described here represents a significant advance over in vitro studies, the absence mia was suppressed to undetectable levels (õ400 copies/mL) in all of the mice after 1 month of treatment with zidovudine-3TC-of HIV-specific human immune responsiveness in these thy/ liv -SCID-hu mice [12] may underestimate the effect of drug ritonavir (100, 100, and 200 mg/kg/day or 10, 10, and 20 mg/kg/ day, respectively) or ritonavir-saquinavir (200 and 2500 mg/kg/ treatment and alter the degree of HIV infection occurring in the lymphoid tissues. Therefore, results obtained using these day, respectively). The level of infection in the hu-thy/liv implants was significantly decreased by treatment with these multidrug mice should be interpreted with caution pending confirmation with human studies. Our modified thy/liv -SCID-hu mice regimens, but low levels of HIV infection were still detectable in the hu-thy/liv implants, a result comparable to that reported for should prove to be a useful system for evaluating whether drug / 9d3f$$fe45 12-23-97 08:09:06 jinfas UC: J Infect
